相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Concordance of tissue- and plasma-derived genomic profiling in CheckMate 9LA, using the FoundationOne CDx and GuardantOMNI assays.
Jonathan F. Baden et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer
Alvida Qvick et al.
MOLECULAR MEDICINE (2021)
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials
A. Galvano et al.
ESMO OPEN (2021)
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer
Charu Aggarwal et al.
CLINICAL CANCER RESEARCH (2020)
Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Cell-Free DNA in Stage I-IV Non-Small Cell Lung Cancer
John Jiang et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2020)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis
Ivo Buchhalter et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
Neal Ready et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
Zhijie Wang et al.
JAMA ONCOLOGY (2019)
A plasma-based assay for assessment of tumour mutational burden in patients with metastatic non-small cell lung cancer in the first-line treatment setting: Results from the MYSTIC study
H. Si et al.
EUROPEAN JOURNAL OF CANCER (2019)
Optimizing panel-based tumor mutational burden (TMB) measurement
J. Budczies et al.
ANNALS OF ONCOLOGY (2019)
Blood-based tumor mutation burden: continued progress toward personalizing immunotherapy in non-small cell lung cancer
Vincent K. Lam et al.
JOURNAL OF THORACIC DISEASE (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions
Albrecht Stenzinger et al.
GENES CHROMOSOMES & CANCER (2019)
Assessment of tumor mutation burden using a novel panel design strategy utilizing highly mutated genomic regions
Amrita Pati et al.
CANCER RESEARCH (2019)
The characteristics of ctDNA reveal the high complexity in matching the corresponding tumor tissues
Nong Yang et al.
BMC CANCER (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) plus ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568
Suresh S. Ramalingam et al.
CANCER RESEARCH (2018)
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Diana Miao et al.
NATURE GENETICS (2018)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara et al.
NATURE MEDICINE (2018)
Complication rates of CT-guided transthoracic lung biopsy: meta-analysis
W. J. Heerink et al.
EUROPEAN RADIOLOGY (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients
Florence Koeppel et al.
PLOS ONE (2017)
Integrated digital error suppression for improved detection of circulating tumor DNA
Aaron M. Newman et al.
NATURE BIOTECHNOLOGY (2016)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Analysis of Pre-Analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ Malignancies
Hui Chen et al.
CANCERS (2015)
FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution
Aaron M. Newman et al.
BIOINFORMATICS (2014)
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Aaron M. Newman et al.
NATURE MEDICINE (2014)
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
Elza C. de Bruin et al.
SCIENCE (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
The Cancer Genome Atlas Pan-Cancer analysis project
John N. Weinstein et al.
NATURE GENETICS (2013)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
分享论文
